CUDC-101
Detailed Description
CUDC-101 is a novel, small-molecule, anticancer agent targeting histone deacetylase (HDAC), EGF receptor (EGFR), and HER2. It is currently in phase I clinical development in patients with solid tumors. CUDC-101 has potent antiproliferative and proapoptotic activity in cultured tumor cells and in vivo xenograft models.
- CUDC-101